TG Therapeutics (FRA:NKB2) Accounts Payable & Accrued Expense : €123.9 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Accounts Payable & Accrued Expense?

TG Therapeutics's quarterly accounts payable & accrued expense declined from Sep. 2024 (€91.4 Mil) to Dec. 2024 (€55.7 Mil) but then increased from Dec. 2024 (€55.7 Mil) to Mar. 2025 (€123.9 Mil).

TG Therapeutics's annual accounts payable & accrued expense declined from Dec. 2022 (€39.7 Mil) to Dec. 2023 (€35.3 Mil) but then increased from Dec. 2023 (€35.3 Mil) to Dec. 2024 (€55.7 Mil).

TG Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for TG Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Accounts Payable & Accrued Expense Chart

TG Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

30.43

45.40

39.67

35.28

55.67

TG Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															80.29	86.84	91.37	55.67	123.89

TG Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

TGTX:USA NKB2:Germany

Address

3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines